Chronic Kidney Disease

In a video, Jay B. Wish, MD, clinical medicine professor at Indiana University School of Medicine reports the efficacy of vadadustat in treating anemia in patients with dialysis-dependent chronic kidney disease is noninferior to darbepoetin alfa.

Among patients with established atherosclerotic heart disease on dialysis, the effect of statins on CV events was modest at best, according to a study published in the American Heart Journal.

Data show Black adults with type 2 diabetes and moderate chronic kidney disease were significantly less likely to receive a metformin prescription compared with white counterparts under an old FDA serum creatinine-based metformin label.

As the combination of bumetanide and chlorthalidone reduced arterial pressure and volume overload in patients with advanced chronic kidney disease, it may be a better treatment when loop diuretics are insufficient, according to a speaker.

Calculations for eGFR were closer to measured GFR without adjustments for race, which suggested adjusting eGFR for race could lead to underdiagnosis of chronic kidney disease among Black patients in the United Kingdom, according to results.

As breath ammonia concentration increased at each chronic kidney disease stage and correlated with eGFR and CKD biomarkers, researchers said it can be used to screen for “non-life threatening or non-serious CKD” at a cutoff of 886 ppb.

Results from a randomized controlled trial showed that metformin provided cardiovascular benefits to patients with chronic kidney disease and metabolic syndrome.

Data presented at ASN Kidney Week showed the mineralocorticoid receptor inhibitor antagonist finerenone was effective in reducing cardiac risk and slowing the progression of chronic kidney disease in patients with diabetes.

Dapagliflozin reduced the worsening of kidney function and the risk of cardiovascular or renal death in patients with chronic kidney disease irrespective of the underlying cause of kidney disease, according to recently presented data.

Patients with anemia and chronic kidney disease who receive roxadustat do not show an increased rate of neoplasm-related treatment-emergent adverse events and treatment-emergent serious adverse events, according to presented data.